Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Is Wall Street Too Eager To Get Excited About Eli Lilly's Alzheimer's Drug?
Is Wall Street Too Eager To Get Excited About Eli Lilly's Alzheimer's Drug?
Is Wall Street Too Eager To Get Excited About Eli Lilly's Alzheimer's Drug?
Submitted by
admin
on October 15, 2012 - 10:36am
Source:
Forbes
News Tags:
Eli Lilly
Alzheimer's disease
solanezumab
Headline:
Is Wall Street Too Eager To Get Excited About Eli Lilly's Alzheimer's Drug?
Do Not Allow Advertisers to Use My Personal information
